Recent News

• 06.09.2025 - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.04.2025 - Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
• 06.03.2025 - Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
• 06.02.2025 - Virtual Investor Event
• 06.02.2025 - Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy
• 05.09.2025 - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 05.06.2025 - Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Recent Filings

• 06.03.2025 - 8-K Current report
• 06.02.2025 - 8-K Current report
• 06.02.2025 - EX-99.1 EX-99.1
• 05.19.2025 - 8-K Current report
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.16.2025 - 4 Statement of changes in beneficial ownership of securities